The sharpest verdict: Bausch + Lomb is advancing a Phase 3 program whose Phase 2 primary endpoint failed, resting the entire regulatory thesis on a prespecified secondary timepoint with undisclosed effect sizes and absent symptom data. The investigational combination of lifitegrast 5% and perfluorohexyloctane missed superiority over lifitegrast monotherapy on total corneal fluorescein staining (tCFS) at day 29 — the original primary endpoint — but demonstrated statistically significant superiority at day 15, a timepoint the FDA has accepted as registrational. [1] Both component monotherapies support early-onset biology: lifitegrast (Xiidra) achieved a treatment effect of 7.85 on eye dryness score at day 14 versus placebo in OPUS-3 (P<0.0001), and perfluorohexyloctane (MIEBO) demonstrated tCFS differences of -0.6 at week 2 in GOBI (P<0.01). [2][3] The combination's day-15 signal is therefore mechanistically plausible, but the day-29 convergence with monotherapy raises an unresolved question: does the combination deliver durable incremental benefit, or does it merely front-load the same magnitude of effect that lifitegrast alone achieves by steady state? [4] No effect sizes or confidence intervals for the day-15 comparison are disclosed in the press release, making clinical meaningfulness assessment impossible at this stage. Critically, no symptom endpoint data (eye dryness score or equivalent) at day 15 are reported; both approved monotherapies met dual co-primary sign-plus-symptom endpoints in their pivotal programs, and payers have consistently required subjective improvement evidence for reimbursement. [5][6] On precedent: the two component monotherapies pass the mechanistic-fit bar as direct analogues, but no clean precedent exists for a dry eye disease combination therapy that failed its Phase 2 primary at day 29 and advanced based solely on an earlier secondary timepoint. Cyclosporine 0.1% (Vevizye, ESSENCE trials) succeeded at both day 15 and day 29 — its day-15 data were concordant, not a rescue. [1] Cyclosporine 0.1% (Ikervis, SANSIKA/SICCANOVE) failed its primary combined endpoint but advanced via six-month data and a severe-subpopulation restriction — neither of which the combination has disclosed. [7] The $700 million peak-sales forecast and 2029 launch target are commercially aggressive given unproven dual endpoint success, likely step-edit payer requirements, and internal cannibalization risk against Bausch + Lomb's own Xiidra and MIEBO franchises. The sharpest remaining risk: if Phase 3 replicates tCFS superiority at day 15 but fails on symptom co-primary or fails to show non-inferiority at day 29, the label will be narrow, payer uptake will be restricted, and the commercial thesis collapses.
The combination failed its Phase 2 primary endpoint (tCFS at day 29 vs. lifitegrast monotherapy); advancement rests on a prespecified but single secondary timepoint (day 15) with no disclosed effect size, confidence intervals, or symptom endpoint result — insufficient to establish dual sign/symptom efficacy at the standard required by Phase 3 precedents. [1][8]
| Indication | dry eye disease |
| Drug | lifitegrast and perfluorohexyloctane |
| Company | Bausch + Lomb |
| Trial Phase | Phase 2, Phase 3 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Neutral / Mixed |
| Therapeutic Area | Immunology |
| Primary Efficacy Goal (Phase 2) | total corneal fluorescein staining (tCFS) at day 29 |
| Significant Treatment Benefit Timepoint | day 15 |
| FDA Accepted Endpoint | day 15 (for tCFS) |
| Number of Patients | More than 440 patients |
| Comparator Arms | Xiidra alone, PHFO alone, three vehicle controls |
| Dosage Frequency | twice daily |
| Peak Sales Forecast | $700 million |
| Estimated Launch Date | 2029 |
| Estimated Phase 3 Data Date | 2028 |
| Regulatory Agency | Food and Drug Administration |
Bausch + Lomb Advances Dual-Action Eye Drop to Phase 3
Bausch + Lomb is advancing its investigational dual-action eye drop, combining 5% lifitegrast and perfluorohexyloctane, into Phase 3 development for dry eye disease. This decision follows Phase 2 results where the therapy missed its primary efficacy goal of improving eye damage, measured by total corneal fluorescein staining (tCFS), at day 29 compared to Xiidra alone. However, a prespecified secondary analysis showed significant superiority at day 15, a timepoint accepted by the FDA as a registrational primary endpoint. The company reaffirmed its forecast of peak sales around $700 million for the drug, with a potential launch in 2029.
- In the Phase 2 study involving over 440 dry eye disease patients, Bausch + Lomb's dual-action eye drop failed to significantly improve total corneal fluorescein staining (tCFS) at day 29 compared to Xiidra alone. Despite missing the primary efficacy goal, the investigational combination did show a numerical favorability over Xiidra alone at this timepoint.
- A prespecified secondary analysis of the Phase 2 data revealed a significant treatment benefit for the dual-action eye drop at day 15 compared to Xiidra alone. This earlier timepoint is recognized by the Food and Drug Administration as an acceptable registrational primary endpoint for tCFS, prompting Bausch + Lomb to advance the candidate into Phase 3 development with day 15 as the new primary endpoint.
- Bausch + Lomb plans to disclose more details on the Phase 3 study design and timeline in the coming months, with the late-stage trial again comparing the dual-action eye drop against its individual components. The company reiterated its previous forecast of Phase 3 data in 2028, a potential launch in 2029, and peak sales of approximately $700 million for the drug.
The Rationale for Bausch + Lomb's Dual-Action Dry Eye Therapy
Recent clinical investigations have explored a range of combination therapy strategies for dry eye disease, targeting multiple pathophysiological mechanisms simultaneously — including tear film instability, ocular surface inflammation, meibomian gland dysfunction, and corneal nerve impairment. These multi-modal approaches consistently outperform monotherapy comparators across key efficacy endpoints.
Platelet-Rich Plasma with Omega-3 Supplementation: Injectable homologous platelet-rich plasma (HPRP) combined with oral omega-3 (ω-3) supplementation demonstrated enhanced tear film stability, reduced ocular inflammation, and superior epithelial repair compared to HPRP alone. TBUT values were significantly higher in the combination group from month 3 onwards (p < 0.05), with histological improvements including reduced lymphocyte and neutrophil infiltration and increased goblet cell density.
Diquafosol Sodium 3% with Sodium Hyaluronate 0.3%: In a prospective randomized controlled study of dry eye following small incision lenticule extraction, this combination significantly outperformed sodium hyaluronate monotherapy at 3 months across OSDI (12.98±7.29 vs. 16.82±8.25; p=0.029), TBUT (5.83±2.02 vs. 4.24±0.94; p=0.0002), and Schirmer I test scores (7.75±3.92 vs. 5.24±3.42; p=0.003).
Loteprednol Etabonate Pretreatment with Cyclosporine A: A multicenter, randomized, double-masked study (n=118) demonstrated that loteprednol etabonate (LE) pretreatment prior to topical cyclosporine A (tCsA) initiation significantly reduced tCsA-associated stinging (p<0.05) and produced superior OSDI improvement versus artificial tears, with additional benefits in Schirmer test, fluorescein staining, and lissamine green staining outcomes.
Intense Pulsed Light with Deproteinized Calf Blood Extract Eye Drops: A prospective study in 23 patients with dry eye disease and concomitant ocular pain found that IPL combined with deproteinized calf blood extract (DCBE) eye drops significantly reduced VAS pain scores, OSDI, corneal fluorescein staining, and meibomian gland secretion quality scores, while improving TBUT, Schirmer I test results, corneal nerve branch density, and neuropeptide substance P levels.
Unpacking the Phase 2 Results for Bausch + Lomb's Eye Drop
The Phase 2 TOP1630 trial represents the pivotal evidence base for Bausch + Lomb's investigational eye drop, enrolling patients with moderate-to-severe dry eye disease (DED) under controlled conditions designed to sensitize symptom detection. Across the broader DED trial landscape, study designs vary considerably in population size, intervention modality, and endpoint selection, reflecting the heterogeneity of the condition and the range of therapeutic mechanisms under investigation.
| Trial | Design | Population | Treatment | Key Endpoints |
|---|---|---|---|---|
| TOP1630 (Phase 2) | Randomized, double-masked, parallel-group, placebo-controlled | 61 subjects with moderate-to-severe DED; OSDI ≥18, Schirmer's ≤10 and ≥1 mm/5 min, TFBUT >1 and <7 sec | 0.1% TOP1630 ophthalmic solution TID vs. placebo for 28 days (7-day placebo run-in) | Ocular discomfort post-CAE (P=0.02); grittiness/foreign body sensation (P<0.05 each); ocular pain VAS (P=0.03); total ocular surface, corneal sum, and conjunctival sum staining (P<0.05 each); worst DED symptom diary (P=0.06) |
| ONSET-2 (OC-01 Varenicline, Phase 3) | Randomized, multicenter, double-masked, vehicle-controlled | 758 adults ≥22 years with DED; OSDI ≥23, Schirmer's ≤10 mm | OC-01 0.03 mg (n=260) or 0.06 mg (n=246) vs. vehicle (n=252) intranasal spray BID for 4 weeks | Primary: ≥10 mm improvement in Schirmer Tear Score (STS) at Week 4 (0.03 mg: 47.3%; 0.06 mg: 49.2%; vehicle: 27.8%; P<0.0001); Secondary: change from baseline in STS and Eye Dryness Score (EDS) in CAE and clinic |
| Topical Omega-3 PUFA (Pilot) | Multicenter, masked-observer, randomized, active-controlled, non-inferiority | 80 patients (37 PUFA; 39 povidone evaluable) | Daily omega-3 PUFA eye drops vs. 2% povidone eye drops for 3 months | Co-primary: mean % change from baseline in TBUT and OSDI at Week 4 (both improved at Weeks 4 and 12; non-inferiority of PUFA demonstrated); Secondary: symptom intensity, corneal fluorescein staining (Oxford scale), tear volume, MMP-9 concentration |
| Eyestil Plus® vs. Vismed Multi® | Randomized, double-blind, multicenter | 96 adults >18 years with moderate-to-severe DED (n=48 per arm; 82.3% female; mean age 65.8 years) | Eyestil Plus® or Vismed Multi® 6× daily for 3 months | Primary: global corneal and conjunctival staining at 1 month (non-inferiority of Eyestil Plus® demonstrated); Secondary: TBUT (P=0.538 at 1 month; P=0.302 at 3 months), Schirmer test (P=0.540 at 3 months), patient-reported outcomes, investigator satisfaction, and safety |
Pivoting to Phase 3: Bausch + Lomb's Endpoint Strategy
Recent dry eye disease (DED) clinical trials have reinforced the dual-endpoint paradigm — capturing both patient-reported symptoms and objective ocular surface signs. The Ocular Surface Disease Index (OSDI) remains a cornerstone primary symptom endpoint, with trials such as SAHARA designating it as a co-primary outcome and using scores of ≥23 as inclusion criteria for moderate-to-severe disease. The Eye Dryness Score (EDS) has gained traction as an alternative symptom measure, most notably in the ONSET trials where an EDS ≥60 defined severe symptomatology and a responder threshold was anchored to clinically meaningful improvement. The Symptom Assessment in Dry Eye (SANDE) instrument has also been validated as a shorter surrogate for OSDI, demonstrating a strong Spearman correlation of 0.7 (p < 0.01), while Visual Analog Scale (VAS) global discomfort scores continue to feature in European trial designs, including the NORTHERN LIGHTS Phase 2 program.
On the signs side, Tear Break-up Time (TBUT) — with an inclusion criterion of ≥1 to ≤7 seconds in SAHARA — and the Schirmer Test Score (STS), used in the ONSET trials with a ≤5 mm threshold for severe disease and ≥10 mm improvement as a responder definition, anchor the objective sign endpoints. Corneal fluorescein staining (CFS), conjunctival lissamine green staining, tear osmolarity, and tear meniscus height (TMH) measured via noninvasive keratography are consistently included as secondary sign endpoints across the trial landscape. Meibomian gland assessments — including the Meibomian Gland Secretion Score (MGSS) with a threshold of ≤12 and meibography-based gland loss grading — have gained particular prominence as the field increasingly recognizes the role of meibomian gland dysfunction in DED pathophysiology.
Emerging biomarker and imaging endpoints reflect a broader shift toward mechanistic disease characterization. HLA-DR expression on conjunctival cells, quantified via flow cytometry from impression cytology, is being evaluated as an inflammatory biomarker — NORTHERN LIGHTS reported a mean baseline expression of 3.4% of cells, with significant association to corneal staining severity (p < 0.01). In vivo confocal microscopy (IVCM) parameters, including corneal nerve fiber density (CND), dendritic cell density (DCD), and microneuroma detection, are advancing as specialized endpoints, particularly in Sjögren syndrome and diabetic DED populations. Noninvasive keratography break-up time (NIKf-BUT) and OCULUS-based meibomian gland loss grading further illustrate the trajectory toward standardized, technology-enabled endpoints that may ultimately support more objective regulatory-grade evidence generation.
A Dual-Action Strategy for Dry Eye Disease
The decision by Bausch + Lomb to advance its dual-action eye drop, combining lifitegrast and perfluorohexyloctane, into Phase 3 development marks a calculated and potentially impactful move in the dry eye disease (DED) therapeutic landscape. DED is a complex, multifactorial condition driven by both inflammation and tear film instability. Existing treatments often target one aspect, such as lifitegrast's anti-inflammatory action by blocking LFA-1/ICAM-1, or perfluorohexyloctane's anti-evaporative properties through lipid layer stabilization. This investigational therapy seeks to offer a more comprehensive solution by addressing both key pathological pathways simultaneously.
While the Phase 2 results presented a nuanced picture—missing the primary efficacy endpoint of total corneal fluorescein staining (tCFS) at day 29, but achieving a prespecified secondary endpoint at day 15—this outcome is not necessarily a setback. The literature indicates that tCFS can be a challenging endpoint in DED trials, with many studies failing to meet it. The FDA's acceptance of a Day 15 endpoint as registrational provides a clear regulatory path forward, mitigating some of the risk associated with the Day 29 miss.
However, the path ahead is not without its challenges. The DED market is highly competitive, with a growing array of approved therapies, including other anti-inflammatory agents, anti-evaporative solutions, and novel mechanisms like varenicline nasal spray, which has shown strong efficacy in tear production. For this combination therapy to achieve its projected $700 million peak sales, it must demonstrate a clear, sustained, and clinically meaningful advantage over these established and emerging options. Furthermore, while both components have known safety profiles, the long-term safety and tolerability of their combined formulation will be critical for patient adoption and adherence. Success in Phase 3 will hinge on robustly demonstrating durable efficacy on both signs and symptoms, coupled with a favorable safety profile, to carve out a significant niche in this dynamic market.
Frequently Asked Questions
References
- [1] Mathebula SD, Khosa PR et al.. Comparison of patient reported dry eye symptoms as evaluated by the ocular surface disease index and symptom assessment. African journal of primary health care & family medicine. 2025 May 21. 40459105
- [2] Tawfik A, Pistilli M et al.. Association of Dry Eye Symptoms and Signs in Patients with Dry Eye Disease. Ophthalmic epidemiology. 2024 Jun. 37592829
- [3] Liu Y, Qian Y et al.. Combination Therapy With Diquafosol Sodium and Sodium Hyaluronate in Eyes With Dry Eye Disease After Small Incision Lenticule Extraction. In vivo (Athens, Greece). 2023 Nov-Dec. 37905613
- [4] Hossain P, Siffel C et al.. Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey. BMJ open. 2021 Mar 4. 33664064
- [5] Macri A, Tarallo M et al.. Imaging Approaches for the Diagnosis of Dry Eye: A Review. Diagnostics (Basel, Switzerland). 2026 Jan 1. 41515623
- [6] Kuklinski EJ, Roy NS et al.. Association of Conjunctival Cell HLA-DR Expression with the Severity of Signs and Symptoms of Dry Eye Disease at Baseline in the NORTHERN LIGHTS Phase 2 Trial. Current eye research. 2025 Jun. 40052360
- [7] Ayres BD, Bloomenstein MR et al.. A Randomized, Controlled Trial Comparing Tearcare(®) and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA). Clinical ophthalmology (Auckland, N.Z.). 2023. 38143559
- [8] Patil S, Sawale G et al.. Quintessence of currently approved and upcoming treatments for dry eye disease. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2025 Feb. 39215848
- [9] Rodriguez JD, Kerti S et al.. Advantages of Lissamine Green Vital Staining as an Endpoint in Dry Eye Clinical Trials. Clinical ophthalmology (Auckland, N.Z.). 2024. 39131543
- [10] Wirta D, Vollmer P et al.. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial. Ophthalmology. 2022 Apr. 34767866
- [11] Pisella PJ, Gain P et al.. A randomised study comparing performance and safety of Eyestil Plus(®) vs Vismed Multi(®) in moderate-to-severe dry eye syndrome patients. European journal of ophthalmology. 2025 Mar. 39094552
- [12] Wu Y, Mou Y et al.. Efficacy of Intense Pulsed Light Combined Blood Extract Eye Drops for Treatment of Nociceptive Pain in Dry Eye Patients. Journal of clinical medicine. 2022 Feb 27. 35268405
- [13] Kaercher T, Messmer EM et al.. Topical Omega-3 Polyunsaturated Fatty Acids for the Treatment of Dry Eye - Results from a Pilot Randomized Controlled Masked-Observer Study. Clinical ophthalmology (Auckland, N.Z.). 2022. 36523849
- [14] Taylor M, Ousler G et al.. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease. Clinical ophthalmology (Auckland, N.Z.). 2019. 30858682
- [15] Sheppard JD, Comstock TL et al.. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure. Advances in therapy. 2016 Apr. 26984315
- [16] Lee CY, Yang SF et al.. The Combination Usage of Dexamethasone and Prednisolone Versus Prednisolone Monotherapy for Inflammation and Intraocular Pressure After Cataract Surgery. Cureus. 2025 Jan. 39897294
- [17] Amparo F, Schaumberg DA et al.. Comparison of Two Questionnaires for Dry Eye Symptom Assessment: The Ocular Surface Disease Index and the Symptom Assessment in Dry Eye. Ophthalmology. 2015 Jul. 25863420
- [18] Guo M, Diaz GM et al.. Association between systemic medication use and severity of dry eye signs and symptoms in the DRy eye assessment and management (DREAM) study. The ocular surface. 2024 Apr. 38307463
- [19] Dana R, Meunier J et al.. Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey. American journal of ophthalmology. 2020 Aug. 32277941
- [20] Chen KY, Chan HC et al.. Efficacy and safety of stem cell therapy for dry eye disease: a systematic review and meta-analysis. Stem cell research & therapy. 2026 May 1. 42067941
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
